원료의약품(API) 시장 예측(-2030년) : 유형별, 역가별, 합성 유형별, 약제 유형별, 치료 용도별, 최종사용자별, 지역별

The global active pharmaceutical ingredients market is projected to reach USD 198.39 billion by 2030 from an estimated USD 144.20 billion in 2025, at a CAGR of 6.6% from 2025 to 2030.

The expansion of the active pharmaceutical ingredients market has been predominantly fueled by the expanding oncology & rare disease and diabetes product pipeline. Over the past few years, type 2 diabetes and obesity care have been reshaped by a new class of peptide-based drugs, most notably Semaglutide, Tirzepatide, Liraglutide, and Dulaglutide. These therapies are transforming patient outcomes and creating significant opportunities across the API supply chain.

The pharmaceutical & biotechnology industry segment accounted for the largest share by end user in 2024.

Based on end users, the market is categorized into the pharmaceutical & biotechnology industry, contract research organizations (CROs), contract manufacturing organizations (CMOs), and other end users. The pharmaceutical & biotechnology industry accounted for the major end-user of active pharmaceutical ingredients (APIs), which are essential for drug development and manufacturing. The pharmaceutical industry has seen increasing manufacturing outsourcing to CMOs in the last 5 years, especially for developing and manufacturing drugs & biologics, such as high-potency drugs, ADCs, among others. However, pharmaceutical and biotechnology companies still dominate the end-user segment by retaining in-house manufacturing for high-value blockbuster drugs and biologics. Additionally, the rising demand for innovative therapies has encouraged continuous investment in research and development, with companies prioritizing the creation of novel drugs and advanced formulations. Together, these trends are expected to further strengthen the growth of the pharmaceutical and biotechnology end-user segment.

The innovative APIs segment accounted for the largest market share in the active pharmaceutical ingredients market by type.

Based on type, the global active pharmaceutical ingredients (API) market is divided into innovative APIs and generic APIs. In 2024, innovative APIs dominated the market, driven by the increasing number of regulatory approvals for new and advanced drugs, which is expected to continue supporting growth over the forecast period. For instance, the US FDA approved more than 50 new molecular entities (NMEs) in 2024, reflecting the rising pace of novel drug development. Innovative APIs, being protected by patents, are typically priced higher than generic APIs, contributing to their larger market share. The segment's growth is further reinforced by the focus of pharmaceutical and biotechnology companies on developing novel therapies for complex and unmet medical needs, including oncology, rare diseases, and biologics. Additionally, investments in research and development, advanced manufacturing capabilities, and regulatory incentives continue to promote the introduction of innovative APIs. These factors position innovative APIs as the leading segment of the global API market, reflecting higher value and strong demand.

The Asia Pacific region is expected to grow at the highest CAGR in the global active pharmaceutical ingredients market during the forecast period.

The market is segmented by region into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. The Asia Pacific region is projected to grow at the highest CAGR during the forecast period. The key factors contributing to market growth include the increasing adoption and demand for high-value therapies, driving manufacturing expansion by global & regional players. In addition, the expansion of CDMOs in the region, which is focused on synthetic and biological therapies, is also helping drive demand for APIs. China, Japan, South Korea, India, and Australia are witnessing the growing adoption of innovative and generic medicine, which is supported by expanding manufacturing facilities in the Asia Pacific region. Furthermore, a combination of cost-efficient manufacturing, expanding generics and biosimilars production, and strong government support for local API manufacturing to reduce dependency on imports. India and China are emerging as global hubs owing to their large-scale production capacity, skilled workforce, and favorable regulatory initiatives, which support the growth of the active pharmaceutical ingredients market in the region.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 70% and Demand Side- 30%
• By Designation: Managers- 45%, CXOs and Directors- 30%, and Executives- 25%
• By Region: North America- 30%, Europe- 30%, Asia Pacific- 30%, Latin America- 5%, and the Middle East & Africa- 5%

Key Companies

Key players in the active pharmaceutical ingredients market include Pfizer (CentreOne) (US), Teva Pharmaceutical Industries Ltd. (Israel), Divi's Laboratories Limited (India), Sandoz Group AG (Switzerland), SK Inc. (South Korea), Merck KGaA (Germany), Dr. Reddy's Laboratories Ltd. (India), Sun Pharmaceutical Industries Ltd. (India), Cipla (India), Aurobindo Pharma (India), Evonik Industries AG (Germany), Hikma Pharmaceuticals plc (UK), BASF SE (Germany), Alembic Pharmaceuticals Limited (India), Siegfried Holding AG (Switzerland), EUROAPI (France), Asymchem (China), Bachem (Switzerland), Zhejiang Huahai Pharmaceutical Co., Ltd. (China), and Zhejiang Hisun (China).

Research Coverage

This research report categorizes the active pharmaceutical ingredients market, Active Pharmaceutical Ingredient Market by type (Innovative, generic), potency (traditional API, highly potent API (synthetic, biologics), synthesis ((synthetic, biotech), products (mAb, hormones, cytokines) expression system), type of drug (OTC, Rx), therapeutics application (diabetes, oncology, CVD), end user (pharma & biotech, CROs CMOs) and region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa).

The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the active pharmaceutical ingredients market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, solutions, key strategies, collaborations, partnerships, and agreements. New approvals/launches, collaborations, acquisitions, and recent developments associated with the active pharmaceutical ingredients market.

Reasons to buy this report

The report will help market leaders and new entrants by providing them with the closest approximations of the revenue numbers for the overall active pharmaceutical ingredients market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their businesses and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:

• Analysis of key drivers (Surge in Demand for Complex APIs, Government Incentives & Supply Chain Reshoring, Adoption of Continuous Manufacturing & Digital Process Controls, Expanding Oncology & Rare Disease Pipeline Driving Outsourcing), restraints (Tightening regulatory requirements, high production costs in Western facilities and price pressure from generic tenders and single-winner procurement policies), opportunities (Critical medicines are commanding premium pricing through dual-sourcing and local manufacturing, China-Plus-One Strategy Boosting India, US, & EU Manufacturing Bases, and Integrated API-to-FDF CDMO Service Models Gaining Traction), and challenges (Supply Chain Concentration Risk, Quality Failures & Site Shutdowns Leading to Global Supply Disruptions, Capital-intensive Investments Needed for High-containment & Advanced Facilities and Geopolitical Tensions & Trade Restrictions Impacting API Flow)
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities in the active pharmaceutical ingredients market
• Market Development: Comprehensive information about lucrative markets across varied regions
• Market Diversification: Exhaustive information about untapped geographies, recent developments, and investments in the active pharmaceutical ingredients market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players. A detailed analysis of the key industry players has been done to provide insights into their key strategies, product launches/ approvals, acquisitions, partnerships, agreements, collaborations, other recent developments, investment and funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the active pharmaceutical ingredients market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 INCLUSIONS AND EXCLUSIONS
• 1.4 STUDY SCOPE
  • 1.4.1 SEGMENTS CONSIDERED
  • 1.4.2 YEARS CONSIDERED
• 1.5 CURRENCY CONSIDERED
• 1.6 STAKEHOLDERS
• 1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Objectives of secondary research
    • 2.1.1.2 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Breakdown of primaries (supply- and demand-side participants)
    • 2.1.2.2 Key objective of primary research
• 2.2 MARKET ESTIMATION
  • 2.2.1 GLOBAL MARKET ESTIMATION
    • 2.2.1.1 Company revenue analysis (Bottom-up approach)
      • 2.2.1.1.1 Revenue share analysis of Pfizer, Inc.
    • 2.2.1.2 MnM repository analysis
    • 2.2.1.3 Primary interviews
  • 2.2.2 INSIGHTS OF PRIMARY EXPERTS
  • 2.2.3 SEGMENTAL MARKET SIZE ESTIMATION (TOP-DOWN APPROACH)
• 2.3 GROWTH RATE PROJECTIONS
• 2.4 DATA TRIANGULATION
• 2.5 RESEARCH ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS
• 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

• 3.1 KEY INSIGHTS AND MARKET HIGHLIGHTS
• 3.2 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST
• 3.3 STRATEGIC IMPERATIVES FOR KEY STAKEHOLDERS
  • 3.3.1 PHARMACEUTICAL CONTRACT MANUFACTURERS
  • 3.3.2 STARTUPS AND INNOVATIVE BIOTECH FIRMS
  • 3.3.3 CDMOS/CROS

4 PREMIUM INSIGHTS

• 4.1 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET OVERVIEW
• 4.2 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE AND COUNTRY, 2025
• 4.3 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HIGHLY POTENT APIS, BY TYPE
• 4.4 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY PRODUCT
• 4.5 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
• 4.6 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: EMERGING VS. DEVELOPED MARKETS, 2025 VS. 2030
• 4.7 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
• 4.8 EMERGING BUSINESS MODELS AND ECOSYSTEM SHIFTS
• 4.9 VC/PRIVATE EQUITY INVESTMENT TRENDS AND STARTUP LANDSCAPE
• 4.10 REGULATORY POLICY INITIATIVES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Surge in demand for complex APIs
    • 5.2.1.2 Favorable government incentives and supply chain reshoring
    • 5.2.1.3 Increasing adoption of continuous manufacturing and digital process controls
    • 5.2.1.4 Rapid growth of oncology and rare disease pipelines
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Tightening regulatory requirements for nitrosamine and impurity controls
    • 5.2.2.2 High production costs in US and Europe-based facilities
    • 5.2.2.3 Price pressure from generic tenders and single-winner procurement policies
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Growing emphasis on supply resilience and security of critical medicine manufacturing
    • 5.2.3.2 China-Plus-One strategy
    • 5.2.3.3 Increasing adoption of integrated CDMO service models
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Capital-intensive investments for high containment and advanced facilities
    • 5.2.4.2 Quality failures and site shutdowns
    • 5.2.4.3 Supply chain concentration risk
    • 5.2.4.4 Geopolitical tensions and trade restrictions
• 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS
• 5.4 PRICING ANALYSIS
  • 5.4.1 INDICATIVE PRICING ANALYSIS, BY KEY PLAYER, 2024
  • 5.4.2 INDICATIVE PRICING ANALYSIS, BY REGION, 2024
• 5.5 TECHNOLOGY ANALYSIS
  • 5.5.1 KEY TECHNOLOGIES
    • 5.5.1.1 Continuous manufacturing
    • 5.5.1.2 Advanced analytical techniques
    • 5.5.1.3 Biocatalysis
  • 5.5.2 COMPLEMENTARY TECHNOLOGIES
    • 5.5.2.1 Data analytics and digitalization
    • 5.5.2.2 Personalized medicines and custom synthesis
    • 5.5.2.3 Supercritical fluid technology
  • 5.5.3 ADJACENT TECHNOLOGIES
    • 5.5.3.1 Supply chain visibility and blockchain
    • 5.5.3.2 3D printing
    • 5.5.3.3 Nanotechnology
• 5.6 SUPPLY CHAIN ANALYSIS
• 5.7 VALUE CHAIN ANALYSIS
  • 5.7.1 RESEARCH & DEVELOPMENT (VALUE ADDITION: 30-35%)
  • 5.7.2 CLINICAL TRIALS & REGULATORY APPROVALS (VALUE ADDITION: 50-70%)
  • 5.7.3 MANUFACTURING (VALUE ADDITION: 70-80%)
  • 5.7.4 MARKETING & COMMERCIALIZATION (VALUE ADDITION: 80-100%)
• 5.8 ECOSYSTEM ANALYSIS
• 5.9 KEY CONFERENCES & EVENTS
• 5.10 REGULATORY ANALYSIS
  • 5.10.1 REGULATORY SCENARIO
    • 5.10.1.1 North America
      • 5.10.1.1.1 US
      • 5.10.1.1.2 Canada
    • 5.10.1.2 Europe
      • 5.10.1.2.1 Germany
      • 5.10.1.2.2 UK
    • 5.10.1.3 Asia Pacific
      • 5.10.1.3.1 Japan
    • 5.10.1.4 Latin America
      • 5.10.1.4.1 Brazil
    • 5.10.1.5 Middle East & Africa
      • 5.10.1.5.1 Saudi Arabia
  • 5.10.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.11 PORTER'S FIVE FORCES ANALYSIS
  • 5.11.1 THREAT OF NEW ENTRANTS
  • 5.11.2 THREAT OF SUBSTITUTES
  • 5.11.3 BARGAINING POWER OF SUPPLIERS
  • 5.11.4 BARGAINING POWER OF BUYERS
  • 5.11.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.12 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.12.2 KEY BUYING CRITERIA
• 5.13 CASE STUDY ANALYSIS
• 5.14 MACROECONOMICS INDICATORS
  • 5.14.1 HEALTHCARE EXPENDITURE TRENDS
  • 5.14.2 GLOBAL CANCER BURDEN
• 5.15 PATENT ANALYSIS
  • 5.15.1 LIST OF PATENTS
• 5.16 UNMET NEEDS AND WHITE SPACES
• 5.17 TRADE DATA
  • 5.17.1 IMPORT DATA FOR HS CODE-2941
  • 5.17.2 EXPORT DATA FOR HS CODE-2941
• 5.18 INVESTMENT AND FUNDING SCENARIO
• 5.19 MANUFACTURING SITES AND CAPACITY EXPANSION OF KEY API SUPPLIERS
• 5.20 IMPACT OF AI/GEN AI ON ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
  • 5.20.1 INTRODUCTION
  • 5.20.2 IMPACT AND MARKET POTENTIAL OF ARTIFICIAL INTELLIGENCE IN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
  • 5.20.3 AI USE CASES
  • 5.20.4 FUTURE OF GENERATIVE AI IN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET ECOSYSTEM
• 5.21 IMPACT OF US TARIFF ON ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
  • 5.21.1 INTRODUCTION
  • 5.21.2 KEY TARIFF RATES
  • 5.21.3 PRICE IMPACT ANALYSIS
  • 5.21.4 IMPACT ON COUNTRY/REGION
    • 5.21.4.1 North America
      • 5.21.4.1.1 US
    • 5.21.4.2 Europe
    • 5.21.4.3 Asia Pacific
  • 5.21.5 IMPACT ON END-USE INDUSTRIES
    • 5.21.5.1 Pharmaceutical & biotechnology industry
    • 5.21.5.2 Contract research organizations (CROs)
    • 5.21.5.3 Contract manufacturing organizations (CMOs)

6 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE

• 6.1 INTRODUCTION
• 6.2 ACTIVE PHARMACEUTICAL INGREDIENTS, BY TYPE (CAPTIVE AND MERCHANT)
• 6.3 INNOVATIVE APIS
  • 6.3.1 INCREASING REGULATORY APPROVALS FOR INNOVATIVE DRUGS TO FACILITATE GROWTH
• 6.4 GENERIC APIS
  • 6.4.1 GROWING FOCUS ON GENERIC DRUGS AND LOW MANUFACTURING COSTS TO FUEL MARKET

7 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY

• 7.1 INTRODUCTION
• 7.2 ACTIVE PHARMACEUTICAL INGREDIENTS, BY POTENCY (CAPTIVE AND MERCHANT)
• 7.3 TRADITIONAL APIS
  • 7.3.1 INCREASING NUMBER OF APPLICATIONS IN THERAPEUTIC AREAS TO AUGMENT GROWTH
• 7.4 HIGHLY POTENT APIS
  • 7.4.1 SYNTHETIC
    • 7.4.1.1 Evolving targeted oncology therapies to stimulate growth
  • 7.4.2 BIOLOGICS
    • 7.4.2.1 Robust product pipeline to encourage growth

8 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS

• 8.1 INTRODUCTION
• 8.2 ACTIVE PHARMACEUTICAL INGREDIENTS, BY TYPE OF SYNTHESIS (CAPTIVE AND MERCHANT)
• 8.3 SYNTHETIC APIS
  • 8.3.1 INNOVATIVE SYNTHETIC APIS
    • 8.3.1.1 High value of innovative APIs to drive market
  • 8.3.2 GENERIC SYNTHETIC APIS
    • 8.3.2.1 Increasing need for generic medicines to contribute to growth
• 8.4 BIOTECH APIS
  • 8.4.1 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE
    • 8.4.1.1 Innovative biotech APIs
      • 8.4.1.1.1 Growing demand for innovative biopharmaceuticals to drive market
    • 8.4.1.2 Generic biotech APIs
      • 8.4.1.2.1 Cost-effectiveness and favorable government efforts to fuel market
  • 8.4.2 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT
    • 8.4.2.1 Monoclonal antibodies
      • 8.4.2.1.1 Growing applications of antibody-drug conjugates in treating cancer to drive market
    • 8.4.2.2 Hormones and growth factors
      • 8.4.2.2.1 Growing incidence of hormonal disorders to drive market
    • 8.4.2.3 Fusion proteins
      • 8.4.2.3.1 Increasing applications of fusion proteins in biopharmaceuticals to aid growth
    • 8.4.2.4 Cytokines
      • 8.4.2.4.1 Rising use of cytokines in cell signaling, inflammation, and cell growth to spur growth
    • 8.4.2.5 Therapeutic enzymes
      • 8.4.2.5.1 Growing significance of enzymes in therapies for cancer and pain management to propel market
    • 8.4.2.6 Blood factors and anti-coagulants
      • 8.4.2.6.1 Growing incidence of hemophilia to fuel market
    • 8.4.2.7 Recombinant vaccines
      • 8.4.2.7.1 Growing prevalence of infectious diseases to fuel market
  • 8.4.3 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM
    • 8.4.3.1 Mammalian expression systems
      • 8.4.3.1.1 Ability to carry post-translational modifications to drive adoption
    • 8.4.3.2 Microbial expression systems
      • 8.4.3.2.1 High expression levels of proteins at low costs to aid growth
    • 8.4.3.3 Yeast expression systems
      • 8.4.3.3.1 Efficient protein secretion and simple purification to contribute to growth
    • 8.4.3.4 Insect expression systems
      • 8.4.3.4.1 Scalability, cost-effectiveness, and favorable safety profile to boost market
    • 8.4.3.5 Other expression systems

9 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG

• 9.1 INTRODUCTION
• 9.2 ACTIVE PHARMACEUTICAL INGREDIENTS, BY TYPE OF DRUG (CAPTIVE AND MERCHANT)
• 9.3 PRESCRIPTION DRUGS
  • 9.3.1 INCREASED ADOPTION OF SPECIALTY DRUGS TO SUPPORT GROWTH
• 9.4 OVER-THE-COUNTER DRUGS
  • 9.4.1 RISING AWARENESS OF PRECAUTIONARY CARE AND HEALTH CONCERNS TO SPUR GROWTH

10 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION

• 10.1 INTRODUCTION
• 10.2 ACTIVE PHARMACEUTICAL INGREDIENTS, BY THERAPEUTIC APPLICATION (CAPTIVE AND MERCHANT)
• 10.3 COMMUNICABLE DISEASES
  • 10.3.1 INCREASING INVESTMENTS IN DEVELOPING NEW ANTIBIOTICS, ANTIVIRALS, ANTIFUNGALS, AND VACCINES TO AID GROWTH
• 10.4 ONCOLOGY
  • 10.4.1 GROWING NUMBER OF FDA APPROVALS TO DRIVE MARKET
• 10.5 DIABETES
  • 10.5.1 RISING ADVANCEMENTS IN TREATMENT OPTIONS TO EXPEDITE GROWTH
• 10.6 CARDIOVASCULAR DISEASES
  • 10.6.1 INCREASING ADOPTION OF GROWTH STRATEGIES BY KEY PLAYERS TO PROMOTE GROWTH
• 10.7 RESPIRATORY DISEASES
  • 10.7.1 INCREASING BURDEN OF RESPIRATORY DISORDERS TO BOLSTER GROWTH
• 10.8 PAIN MANAGEMENT
  • 10.8.1 RISING DEMAND FOR INNOVATIVE AND ADVANCED PAIN MEDICATIONS TO BOLSTER GROWTH
• 10.9 OTHER THERAPEUTIC APPLICATIONS

11 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER

• 11.1 INTRODUCTION
• 11.2 ACTIVE PHARMACEUTICAL INGREDIENTS, BY END USER (CAPTIVE AND MERCHANT)
• 11.3 PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRY
  • 11.3.1 RISE IN NEED OF NOVEL TREATMENTS TO EXPEDITE GROWTH
• 11.4 CONTRACT RESEARCH ORGANIZATIONS
  • 11.4.1 INCREASING OUTSOURCING OF DRUG R&D ACTIVITIES TO SUPPORT GROWTH
• 11.5 CONTRACT MANUFACTURING ORGANIZATIONS
  • 11.5.1 GROWING FOCUS ON BETTER QUALITY AND REGULATORY COMPLIANCE TO DRIVE MARKET
• 11.6 OTHER END USERS

12 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION

• 12.1 INTRODUCTION
• 12.2 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION (CAPTIVE AND MERCHANT)
• 12.3 NORTH AMERICA
  • 12.3.1 MACROECONOMIC ANALYSIS OF NORTH AMERICA
  • 12.3.2 US
    • 12.3.2.1 High clinical trial & drug discovery activity and efficient regulatory environment to expedite growth
  • 12.3.3 CANADA
    • 12.3.3.1 Favorable government support and strong product pipeline to sustain growth
• 12.4 EUROPE
  • 12.4.1 MACROECONOMIC ANALYSIS OF EUROPE
  • 12.4.2 GERMANY
    • 12.4.2.1 High healthcare expenditure and advanced R&D facilities to drive market
  • 12.4.3 UK
    • 12.4.3.1 Rising government investments and growing focus on personalized treatment to fuel market
  • 12.4.4 FRANCE
    • 12.4.4.1 Increased focus on domestic manufacturing to promote growth
  • 12.4.5 ITALY
    • 12.4.5.1 Rising commercial drug development to favor growth
  • 12.4.6 SPAIN
    • 12.4.6.1 Increase in generic drug manufacturing capacity to propel market
  • 12.4.7 HUNGARY
    • 12.4.7.1 Increasing manufacturing activities in pharmaceutical sector to drive market
  • 12.4.8 REST OF EUROPE
• 12.5 ASIA PACIFIC
  • 12.5.1 MACROECONOMIC ANALYSIS OF ASIA PACIFIC
  • 12.5.2 CHINA
    • 12.5.2.1 Rise in government policies to increase medicine access and affordability to support growth
  • 12.5.3 JAPAN
    • 12.5.3.1 Growing geriatric population to boost market
  • 12.5.4 INDIA
    • 12.5.4.1 Increasing R&D activities and rising government funding initiatives to favor growth
  • 12.5.5 SOUTH KOREA
    • 12.5.5.1 Rising annual drug exports to drive market
  • 12.5.6 AUSTRALIA
    • 12.5.6.1 Increasing demand for innovative APIs to propel market
  • 12.5.7 REST OF ASIA PACIFIC
• 12.6 LATIN AMERICA
  • 12.6.1 LATIN AMERICA: MACROECONOMIC ANALYSIS
  • 12.6.2 BRAZIL
    • 12.6.2.1 Increased government investments in pharmaceutical R&D to drive market
  • 12.6.3 MEXICO
    • 12.6.3.1 Rising investments by foreign firms to support market growth
  • 12.6.4 REST OF LATIN AMERICA
• 12.7 MIDDLE EAST
  • 12.7.1 MACROECONOMIC ANALYSIS OF MIDDLE EAST
  • 12.7.2 ISRAEL
    • 12.7.2.1 Highly educated workforce and strong culture of innovations to support growth
  • 12.7.3 GCC COUNTRIES
    • 12.7.3.1 Saudi Arabia
      • 12.7.3.1.1 Growing healthcare expenditure to boost market
    • 12.7.3.2 UAE
      • 12.7.3.2.1 Rising demand for technologically advanced manufacturing processes to aid growth
    • 12.7.3.3 Rest of GCC Countries
  • 12.7.4 REST OF MIDDLE EAST
• 12.8 AFRICA
  • 12.8.1 GROWING DEMAND FOR PHARMACEUTICAL PRODUCTS TO PROPEL MARKET
  • 12.8.2 MACROECONOMIC OUTLOOK FOR AFRICA

13 COMPETITIVE LANDSCAPE

• 13.1 INTRODUCTION
• 13.2 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
• 13.3 REVENUE ANALYSIS, 2022-2024
• 13.4 MARKET SHARE ANALYSIS, 2024
• 13.5 COMPANY VALUATION AND FINANCIAL METRICS
  • 13.5.1 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
• 13.6 BRAND/PRODUCT COMPARISON
• 13.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 13.7.1 STARS
  • 13.7.2 EMERGING LEADERS
  • 13.7.3 PERVASIVE PLAYERS
  • 13.7.4 PARTICIPANTS
  • 13.7.5 COMPETITIVE BENCHMARKING, 2024
    • 13.7.5.1 Company footprint
    • 13.7.5.2 Region Footprint
    • 13.7.5.3 Type footprint
    • 13.7.5.4 Potency footprint
    • 13.7.5.5 Therapeutic application footprint
• 13.8 COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
  • 13.8.1 PROGRESSIVE COMPANIES
  • 13.8.2 RESPONSIVE COMPANIES
  • 13.8.3 DYNAMIC COMPANIES
  • 13.8.4 STARTING BLOCKS
  • 13.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
    • 13.8.5.1 Detailed list of key startups/SMEs
    • 13.8.5.2 Competitive benchmarking of key startups/SMEs
• 13.9 COMPETITIVE SCENARIO
  • 13.9.1 PRODUCT APPROVALS
  • 13.9.2 DEALS
  • 13.9.3 EXPANSIONS

14 COMPANY PROFILES

• 14.1 KEY PLAYERS
  • 14.1.1 PFIZER INC.
    • 14.1.1.1 Business overview
    • 14.1.1.2 Products offered
    • 14.1.1.3 Recent developments
      • 14.1.1.3.1 Expansions
    • 14.1.1.4 MnM view
      • 14.1.1.4.1 Key strengths
      • 14.1.1.4.2 Strategic choices
      • 14.1.1.4.3 Weaknesses and competitive threats
  • 14.1.2 DIVI'S LABORATORIES LIMITED
    • 14.1.2.1 Business overview
    • 14.1.2.2 Products offered
    • 14.1.2.3 Recent developments
      • 14.1.2.3.1 Deals
      • 14.1.2.3.2 Expansions
    • 14.1.2.4 MnM view
      • 14.1.2.4.1 Key strengths
      • 14.1.2.4.2 Strategic choices
      • 14.1.2.4.3 Weaknesses and competitive threats
  • 14.1.3 ASYMCHEM INC.
    • 14.1.3.1 Business overview
    • 14.1.3.2 Products offered
    • 14.1.3.3 Recent developments
      • 14.1.3.3.1 Deals
      • 14.1.3.3.2 Expansions
    • 14.1.3.4 MnM view
      • 14.1.3.4.1 Key strengths
      • 14.1.3.4.2 Strategic choices
      • 14.1.3.4.3 Weaknesses and competitive threats
  • 14.1.4 CIPLA
    • 14.1.4.1 Business overview
    • 14.1.4.2 Products offered
    • 14.1.4.3 Recent developments
      • 14.1.4.3.1 Deals
    • 14.1.4.4 MnM view
      • 14.1.4.4.1 Key strengths
      • 14.1.4.4.2 Strategic choices
      • 14.1.4.4.3 Weaknesses and competitive threats
  • 14.1.5 EVONIK
    • 14.1.5.1 Business overview
    • 14.1.5.2 Products offered
    • 14.1.5.3 Recent developments
      • 14.1.5.3.1 Deals
      • 14.1.5.3.2 Expansions
    • 14.1.5.4 MnM view
      • 14.1.5.4.1 Key strengths
      • 14.1.5.4.2 Strategic choices
      • 14.1.5.4.3 Weaknesses and competitive threats
  • 14.1.6 TEVA PHARMACEUTICAL INDUSTRIES LTD.
    • 14.1.6.1 Business overview
    • 14.1.6.2 Products offered
    • 14.1.6.3 Recent developments
      • 14.1.6.3.1 Other developments
  • 14.1.7 SANDOZ GROUP AG
    • 14.1.7.1 Business overview
    • 14.1.7.2 Products offered
    • 14.1.7.3 Recent developments
      • 14.1.7.3.1 Expansions
  • 14.1.8 SK INC.
    • 14.1.8.1 Business overview
    • 14.1.8.2 Products offered
    • 14.1.8.3 Recent developments
      • 14.1.8.3.1 Deals
      • 14.1.8.3.2 Expansions
  • 14.1.9 MERCK KGAA
    • 14.1.9.1 Business overview
    • 14.1.9.2 Products offered
    • 14.1.9.3 Recent developments
      • 14.1.9.3.1 Deals
      • 14.1.9.3.2 Expansions
  • 14.1.10 DR. REDDY'S LABORATORIES LTD.
    • 14.1.10.1 Business overview
    • 14.1.10.2 Products offered
    • 14.1.10.3 Recent developments
      • 14.1.10.3.1 Expansions
      • 14.1.10.3.2 Other developments
  • 14.1.11 SUN PHARMACEUTICAL INDUSTRIES LTD.
    • 14.1.11.1 Business overview
    • 14.1.11.2 Products offered
    • 14.1.11.3 Recent developments
      • 14.1.11.3.1 Deals
  • 14.1.12 AUROBINDO PHARMA LIMITED
    • 14.1.12.1 Business overview
    • 14.1.12.2 Products offered
    • 14.1.12.3 Recent developments
      • 14.1.12.3.1 Deals
  • 14.1.13 HIKMA PHARMACEUTICALS PLC
    • 14.1.13.1 Business overview
    • 14.1.13.2 Products offered
    • 14.1.13.3 Recent developments
      • 14.1.13.3.1 Deals
      • 14.1.13.3.2 Expansions
  • 14.1.14 BASF
    • 14.1.14.1 Business overview
    • 14.1.14.2 Products offered
  • 14.1.15 ALEMBIC PHARMACEUTICALS LIMITED
    • 14.1.15.1 Business overview
    • 14.1.15.2 Products offered
    • 14.1.15.3 Recent developments
      • 14.1.15.3.1 Product launches and approvals
  • 14.1.16 SIEGFRIED HOLDING AG
    • 14.1.16.1 Business overview
    • 14.1.16.2 Products offered
    • 14.1.16.3 Recent developments
      • 14.1.16.3.1 Deals
      • 14.1.16.3.2 Expansions
  • 14.1.17 EUROAPI
    • 14.1.17.1 Business overview
    • 14.1.17.2 Products offered
    • 14.1.17.3 Recent developments
      • 14.1.17.3.1 Expansions
  • 14.1.18 BACHEM
    • 14.1.18.1 Business overview
    • 14.1.18.2 Products offered
  • 14.1.19 ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD.
    • 14.1.19.1 Business overview
    • 14.1.19.2 Products offered
  • 14.1.20 ZHEJIANG HISUN PHARMACEUTICAL CO., LTD.
    • 14.1.20.1 Business overview
    • 14.1.20.2 Products offered
• 14.2 OTHER PLAYERS
  • 14.2.1 POLYPEPTIDE GROUP
  • 14.2.2 GRANULES INDIA
  • 14.2.3 CORDEN PHARMA
  • 14.2.4 RECIPHARM
  • 14.2.5 ABURAIHAN PHARMACEUTICAL COMPANY
  • 14.2.6 CURIA GLOBAL, INC.
  • 14.2.7 CAMBREX CORPORATION
  • 14.2.8 API PHARMA TECH
  • 14.2.9 SREEPATHI PHARMACEUTICALS LIMITED
  • 14.2.10 SHILPA MEDICARE LIMITED
  • 14.2.11 NANJING JIANYOU BIOCHEMICAL PHARMACEUTICAL CO., LTD.
  • 14.2.12 HOVIONE
  • 14.2.13 CHEMCON GMBH
  • 14.2.14 PHARCO PHARMACEUTICALS
  • 14.2.15 SAMBI PHARMA PVT. LTD.

15 DISCUSSION GUIDE

• 15.1 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 15.2 CUSTOMIZATION OPTIONS
• 15.3 RELATED REPORTS
• 15.4 AUTHOR DETAILS